SUCCESSFUL REVERSAL OF PRIMARY GRAFT NONFUNCTION IN A LIVER-TRANSPLANT PATIENT TREATED WITH PROSTAGLANDIN-E1

被引：10

作者：

ISAI, H ^{[1
]}

SHEIL, AGR ^{[1
]}

MCCAUGHAN, G ^{[1
]}

DOLAN, P ^{[1
]}

WAUGH, R ^{[1
]}

机构：

[1] ROYAL PRINCE ALFRED HOSP,AUSTRALIAN NATL LIVER TRANSPLANTAT UNIT,LEVEL 11,E BLOCK,CAMPERDOWN,NSW 2050,AUSTRALIA

来源：

AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY | 1992年 / 62卷 / 04期

关键词：

LIVER TRANSPLANT; PRIMARY NON-FUNCTION; PROSTAGLANDIN-E1;

D O I：

10.1111/j.1445-2197.1992.tb07563.x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

A 63 year old woman with liver failure received a transplant from a 21 year old male diagnosed as brain dead following a motor accident. After the operation, bile production was virtually absent and aspartate transaminase (AST) values rose dramatically 40 h postoperatively. Primary non-function of the graft was diagnosed, and the patient put on an urgent list for retransplantation. At the same time a continuous intravenous infusion of PGE1 was administered. Aspartate transaminase levels decreased within 9 h and reached normal levels by the sixth postoperative day, when bile production began to increase. Liver function subsequently returned to normal.

引用

页码：314 / 316

页数：3

共 22 条

[1]

Prium J., van Woerden W.F., Knol E., Et al., Donor data in liver grafts with primary non‐function: a preliminary analysis by the European Liver Registry, Transplant. Proc., 21, (1989)

[2]

Greig P.D., Woolf G.M., Sinclair S.B., Et al., Treatment of primary liver graft non‐function with Prostaglandin E<sub>1</sub>, Transplantation, 48, (1989)

[3]

Friend P.J., Lim S., Smith M., Et al., Liver transplantation in the Cambridge/King's College Hospital series: the first 400 patients, Transplant. Proc., 21, (1989)

[4]

Makowka L., Gordon R.D., Todo S., Et al., Analysis of donor criteria for the prediction of outcome in clinical liver transplantation, Transplant. Proc., 19, (1987)

[5]

Bismuth H., Castaing D., Ericzon B.G., Et al., Hepatic transplantation in Europe. First report of the European Liver Transplant Registry, Lancet, 2, (1987)

[6]

Vacanti J.P., Lillehei C.W., Jenkins R.L., Et al., Liver transplantation in children: the Boston Center experience in the first 30 months, Transplant. Proc., 19, (1987)

[7]

Broelsch C.E., Emond J.C., Thistlethwaite J.R., Et al., Liver transplantation, including the concept of reduced‐size liver transplants in children, Ann. Surg., 208, (1988)

[8]

Kahn D., Esquivel C.O., Makowka L., Et al., Causes of death after liver transplantation in children treated with cyclosporine and steroid, Clin. Transplantation, 3, (1989)

[9]

Otte J.B., de Ville, Goyet J., Sokal E., Et al., Size reduction of the donor liver is a safe way to alleviate the shortage of size‐matched organs in paediatric liver transplantation, Ann. Surg., 211, (1990)

[10]

Sinclair S.B., Greig P.D., Blendis L.M., Et al., Biochemical and clinical response of fulminant viral hepatitis to administration of Prostaglandin E<sub>1</sub>, J. Clin. Invest., 84, (1989)

← 1 2 3 →